This article first appeared on GuruFocus .
Release Date: July 16, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Bonesupport Holding AB ( BOEUF ) reported a 30% growth in net sales at constant exchange rates compared to Q2 2025.
-
The company achieved a strong adjusted operating margin of 29%, reflecting effective cost management.
-
Operating cash flows were robust, reaching 67 million SEK, contributing to a solid cash position of 434 million SEK at quarter-end.
-
Sales in the U.S. showed strong traction, particularly for the product SEN, with a 31% growth at constant exchange rates.
-
The regulatory process for CERMET-D is progressing as planned, potentially introducing a new product category upon market authorization.
Negative Points
-
Growth of Cerament G in the U.S. was slightly lower than expected due to some customers implementing usage restrictions.
-
The company faced a $2.7 million inventory write-down and continued impact from U.S. tariffs, affecting gross margins.
-
Selling and marketing expenses increased, driven by commercial investments, impacting short-term profitability.
-
There is volatility in the Middle East affecting market presence and logistics due to geopolitical unrest.
-
The proposed CMS reimbursement changes are still pending, creating uncertainty around future financial impacts.
Q & A Highlights
Q: Can you provide more details on the "stop-go" dynamic in the U.S. market? Are these accounts typical or do they have special characteristics? A: The "stop-go" dynamic is observed in a handful of our top 60 accounts. These accounts are not specific to any niche or category and are unrelated to each other. They continue to use our products at high volumes, albeit slightly reduced compared to Q2 2025. We are in ongoing discussions with them to encourage a return to previous usage levels and further growth. (Respondent: CEO)
Q: What arguments are needed to convince hospitals to resume higher usage of your products without restrictions? A: The issue is not about new evidence but about gaining access at more levels within the hospital as usage increases. We need to ensure that we engage more proactively with hospital administrators using existing data to prevent the "stop-go" dynamic. The upcoming CMS ruling and the Solario study publication are expected to strengthen our case. (Respondent: CEO)
Q: What is your historical success rate in overcoming administrative restrictions, and what feedback have you received on reimbursement changes? A: Historically, we've been successful in overcoming these restrictions more than 60% of the time. Regarding reimbursement changes, while feedback has been positive, it is still early as the ruling is proposed and not yet finalized. (Respondent: CEO)
Q: Did you experience any impact from lower overall procedure volumes in the U.S. during Q2? A: While external data suggests a reduction in procedure volumes, it is difficult to confirm its impact on our results due to our strong growth rate. We are growing significantly, so attributing our results to a reduction in volume would not be accurate. (Respondent: CEO)
Q: Can you provide insights into the growth dynamics in Europe and the rest of the world? A: Growth in Europe is broad across direct, hybrid, and distributor markets. Germany has stabilized, and the UK is neutral. India is progressing according to plan but remains small. Overall, growth is solid across most countries, despite a lower base last year. (Respondent: CEO)
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
